What's Going On With Vaccine Stocks Today? Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed that its advisers will meet this week.
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped. The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness.
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN) Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves.
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks. There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight.
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting other manufacturers.
Why Is Summit Therapeutics Stock Trading Higher On Monday? Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial.
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision.
BioNTech Surges On Summit's Coattails. But Can They Take On Merck? BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study.
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025.
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.
